48 related articles for article (PubMed ID: 23101661)
1. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma.
Xu Y; Wang H; Zhou S; Yu M; Wang X; Fu K; Qian Z; Zhang H; Qiu L; Liu X; Wang P
Leuk Lymphoma; 2013 Jul; 54(7):1396-404. PubMed ID: 23101661
[TBL] [Abstract][Full Text] [Related]
2. Risk of non-Hodgkin lymphoma after radiotherapy for solid cancers.
Kim CJ; Freedman DM; Curtis RE; Berrington de Gonzalez A; Morton LM
Leuk Lymphoma; 2013 Aug; 54(8):1691-7. PubMed ID: 23193978
[TBL] [Abstract][Full Text] [Related]
3. Second primary cancers following non-Hodgkin's lymphoma in Japan: increased risk of hepatocellular carcinoma.
Tanaka H; Tsukuma H; Teshima H; Ajiki W; Koyama Y; Kinoshita N; Masaoka T; Oshima A
Jpn J Cancer Res; 1997 Jun; 88(6):537-42. PubMed ID: 9263530
[TBL] [Abstract][Full Text] [Related]
4. Stomach cancer risk after treatment for hodgkin lymphoma.
Morton LM; Dores GM; Curtis RE; Lynch CF; Stovall M; Hall P; Gilbert ES; Hodgson DC; Storm HH; Johannesen TB; Smith SA; Weathers RE; Andersson M; Fossa SD; Hauptmann M; Holowaty EJ; Joensuu H; Kaijser M; Kleinerman RA; Langmark F; Pukkala E; Vaalavirta L; van den Belt-Dusebout AW; Fraumeni JF; Travis LB; Aleman BM; van Leeuwen FE
J Clin Oncol; 2013 Sep; 31(27):3369-77. PubMed ID: 23980092
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study.
Reulen RC; Winter DL; Diallo I; Veres C; Llanas D; Allodji RS; Bagnasco F; Bárdi E; Feijen EAM; Alessi D; Fidler-Benaoudia MM; Høgsholt S; Teepen JC; Linge H; Haddy N; Byrne J; Debiche G; Grabow D; Gudmundsdottir T; Fauchery R; Zrafi W; Michel G; Øfstaas H; Kaatsch P; Vu-Bezin G; Jenkinson H; Kaiser M; Skinner R; Cole T; Waespe N; Sommer G; Nordenfelt S; Jankovic M; Lähteenmäki Taalas T; Maule MM; van der Pal HJH; Ronckers CM; van Leeuwen FE; Kok JL; Terenziani M; Winther Gunnes M; Wiebe T; Sacerdote C; Jakab Z; Haupt R; Lähteenmäki PM; Zadravec Zaletel L; Kuehni CE; Winther JF; Kremer LCM; Hjorth L; de Vathaire F; Hawkins MM
J Clin Oncol; 2023 Jul; 41(21):3735-3746. PubMed ID: 37235821
[TBL] [Abstract][Full Text] [Related]
6. Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR.
Scholz-Kreisel P; Becker C; Kaiser M; Mahmoudpour SH; Voigt M; Ressing M; Blettner M; Calaminus G; Baust K; Scholtes C; Zimmermann M; Zeissig SR; Schmidberger H; Karle H; Meyer-Oldenburg S; Kaatsch P; Spix C
Cancer Causes Control; 2024 Jan; 35(1):33-41. PubMed ID: 37530985
[TBL] [Abstract][Full Text] [Related]
7. Genetic risk of second malignant neoplasm after childhood cancer treatment: A systematic review.
Ducos C; Aba N; Rosselli F; Fresneau B; Al Ahmad Nachar B; Zidane M; de Vathaire F; Benhamou S; Haddy N
Cancer Epidemiol Biomarkers Prev; 2024 May; ():. PubMed ID: 38801411
[TBL] [Abstract][Full Text] [Related]
8. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.
Travis LB; Curtis RE; Glimelius B; Holowaty EJ; Van Leeuwen FE; Lynch CF; Hagenbeek A; Stovall M; Banks PM; Adami J
J Natl Cancer Inst; 1995 Apr; 87(7):524-30. PubMed ID: 7707439
[TBL] [Abstract][Full Text] [Related]
9. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM; Neppelenbroek SIM; Aleman BMP; Janus CPM; Krol ADG; van Spronsen DJ; Plattel WJ; Roesink JM; Verschueren KMS; Zijlstra JM; Koene HR; Nijziel MR; Schimmel EC; de Jongh E; Ong F; Te Boome LCJ; van Rijn RS; Böhmer LH; Ta BDP; Visser HPJ; Posthuma EFM; Bilgin YM; Muller K; van Kampen D; So-Osman C; Vermaat JSP; de Weijer RJ; Kersten MJ; van Leeuwen FE; Schaapveld M
ESMO Open; 2024 Feb; 9(2):102248. PubMed ID: 38350338
[TBL] [Abstract][Full Text] [Related]
10. Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis.
Lim W; Moon S; Lee NR; Shin HG; Yu SY; Lee JE; Kim I; Ko KP; Park SK
Sci Rep; 2024 Jan; 14(1):413. PubMed ID: 38172159
[TBL] [Abstract][Full Text] [Related]
11. Research Progress of Multiple Primary Malignancies Associated With Esophageal Cancer.
Cui Y; Ren W; Du X; Yang L; Tan B
Cancer Control; 2023; 30():10732748231176641. PubMed ID: 37212379
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and prognosis of double primary malignant neoplasms in patients with non-hodgkin lymphoma.
Zhan Z; Guo W; Li J; Wan X; Guo J; Bai O
Discov Oncol; 2023 May; 14(1):54. PubMed ID: 37133771
[TBL] [Abstract][Full Text] [Related]
13. Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors.
Pan SY; Huang CP; Chen WC
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010291
[TBL] [Abstract][Full Text] [Related]
14. The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study.
Dinnessen MAW; Visser O; Tonino SH; van der Poel MWM; Blijlevens NMA; Kersten MJ; Lugtenburg PJ; Dinmohamed AG
EJHaem; 2020 Nov; 1(2):489-497. PubMed ID: 35844986
[TBL] [Abstract][Full Text] [Related]
15. Trends in the risk of second primary malignances after non-Hodgkin's lymphoma.
Li J; Peng F; Huang H; Cai Z
Am J Cancer Res; 2022; 12(6):2863-2875. PubMed ID: 35812045
[TBL] [Abstract][Full Text] [Related]
16. Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.
Rolf D; Reinartz G; Rehn S; Kittel C; Eich HT
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205623
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia.
Braunstein Z; McLaughlin E; Mishra A; Brammer JE
Blood Adv; 2022 Apr; 6(8):2685-2687. PubMed ID: 34996100
[No Abstract] [Full Text] [Related]
18. Current Status of Management and Outcome for Patients with Ewing Sarcoma.
Hesla AC; Papakonstantinou A; Tsagkozis P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801953
[TBL] [Abstract][Full Text] [Related]
19. Lymphoma masquerading as occlusive retinal vasculitis: A case study.
Sonne SJ; Shieh WS; Srivastava SK; Smith BT
Am J Ophthalmol Case Rep; 2020 Sep; 19():100777. PubMed ID: 32613135
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
